377 related articles for article (PubMed ID: 30858847)
1. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.
Trojnar E; Józsi M; Szabó Z; Réti M; Farkas P; Kelen K; Reusz GS; Szabó AJ; Garam N; Mikes B; Sinkovits G; Mező B; Csuka D; Prohászka Z
Front Immunol; 2019; 10():240. PubMed ID: 30858847
[TBL] [Abstract][Full Text] [Related]
2. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
3. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
[TBL] [Abstract][Full Text] [Related]
4. HUS and TTP: traversing the disease and the age spectrum.
Donadelli R; Sinha A; Bagga A; Noris M; Remuzzi G
Semin Nephrol; 2023 Jul; 43(4):151436. PubMed ID: 37949684
[TBL] [Abstract][Full Text] [Related]
5. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
Farkas P; Csuka D; Mikes B; Sinkovits G; Réti M; Németh E; Rácz K; Madách K; Gergely M; Demeter J; Prohászka Z
Immunobiology; 2017 Feb; 222(2):119-127. PubMed ID: 27771173
[TBL] [Abstract][Full Text] [Related]
6. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
8. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
Mannucci PM; Cugno M
Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
[TBL] [Abstract][Full Text] [Related]
9. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.
Peyvandi F; Rossio R; Ferrari B; Lotta LA; Pontiggia S; Ghiringhelli Borsa N; Pizzuti M; Donadelli R; Piras R; Cugno M; Noris M
J Thromb Haemost; 2016 Feb; 14(2):340-5. PubMed ID: 26613809
[TBL] [Abstract][Full Text] [Related]
11. Influenza-associated thrombotic microangiopathies.
Bitzan M; Zieg J
Pediatr Nephrol; 2018 Nov; 33(11):2009-2025. PubMed ID: 28884355
[TBL] [Abstract][Full Text] [Related]
12. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
Laurence J
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
[TBL] [Abstract][Full Text] [Related]
13. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
Kistler AD
Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
[TBL] [Abstract][Full Text] [Related]
14. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
Williams LA; Marques MB;
Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of complement mediated thrombotic microangiopathies.
Cataland SR; Wu HM
Blood Rev; 2014 Mar; 28(2):67-74. PubMed ID: 24534133
[TBL] [Abstract][Full Text] [Related]
16. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
Westra D; Volokhina EB; van der Molen RG; van der Velden TJ; Jeronimus-Klaasen A; Goertz J; Gracchi V; Dorresteijn EM; Bouts AH; Keijzer-Veen MG; van Wijk JA; Bakker JA; Roos A; van den Heuvel LP; van de Kar NC
Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086
[TBL] [Abstract][Full Text] [Related]
17. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
18. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Wada H; Matsumoto T; Yamashita Y
Semin Thromb Hemost; 2014 Nov; 40(8):866-73. PubMed ID: 25377323
[TBL] [Abstract][Full Text] [Related]
19. The role of von Willebrand factor in thrombotic microangiopathy.
Noone DG; Riedl M; Licht C
Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411
[TBL] [Abstract][Full Text] [Related]
20. [Thrombotic microangiopathy : Relevant new aspects for intensive care physicians].
Gaggl M; Aigner C; Sunder-Plassmann G; Schmidt A
Med Klin Intensivmed Notfmed; 2016 Jun; 111(5):434-9. PubMed ID: 27255224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
